Fiserv's Q4 Earnings Disappoint, Leading to Share Decline and Management Changes
Money

Fiserv's Q4 Earnings Disappoint, Leading to Share Decline and Management Changes

authorBy Chika Uwazie
DateMar 16, 2026
Read time3 min

Fiserv, a prominent financial technology company, recently saw its shares plummet after it failed to meet its fourth-quarter earnings projections and subsequently lowered its financial outlook for the entire year. This downturn was compounded by announcements of leadership changes and a strategic reorientation within the company, raising questions among investors about its future operational effectiveness and growth trajectory. Consequently, investment firms like Artisan Value Fund, which had previously held a stake in Fiserv, have opted to sell off their shares, citing a lack of clarity on the underlying issues impacting the company's merchant acceptance and financial solutions sectors, as well as doubts about the management's trustworthiness.

Artisan Partners, an investment management firm, released its investor letter for the fourth quarter of 2025, detailing the performance of its “Artisan Value Fund.” The fund aims to identify and invest in undervalued companies that possess robust financial health and compelling business models. In 2025, the fund's portfolio delivered a return of 14.28%, slightly trailing the Russell 1000® Value Index's 15.91%. However, over three, five, and ten-year periods, the portfolio consistently surpassed the index, showcasing the effectiveness of its investment approach. The fund's top five holdings from 2025 provide insights into its strategic selections for that year.

Among the companies discussed in Artisan Value Fund's fourth-quarter 2025 investor letter was Fiserv, Inc. (NASDAQ:FISV). This American financial technology company specializes in providing a range of technology services and solutions. By March 13, 2026, Fiserv, Inc. (NASDAQ:FISV) shares were trading at $56.74 each. Over the preceding month, the stock registered a decline of 4.41%, yet it had impressively gained 73.99% over the past 52 weeks, reaching a market capitalization of $30.518 billion.

The investment firm expressed its disappointment with Fiserv's performance, noting that its shares declined sharply after the company's earnings significantly missed expectations, leading to a revised full-year forecast. The situation was further complicated by the announcement of several executive team changes and a new strategic direction, which collectively created uncertainty regarding the company's ability to execute its plans and achieve future growth. The CEO, Mike Lyons, who assumed his role in May 2025 after joining in January, attributed the issues to his predecessors' overly optimistic growth targets and decisions to cut costs and defer investments. While these actions temporarily boosted margins, they ultimately compromised the company's technological capabilities and product development efforts. Given the ambiguity surrounding the deceleration in its merchant acceptance and financial solutions segments, coupled with lingering doubts about the management's credibility, the Artisan Value Fund decided to liquidate its holdings in Fiserv and reallocate its capital to other investment opportunities.

Fiserv, Inc. (NASDAQ:FISV) is not currently featured on our list of the 40 most favored stocks among hedge funds as of the close of 2025. Although we acknowledge Fiserv, Inc.'s potential as an investment, we believe there are other artificial intelligence (AI) stocks that present more attractive upside potential with reduced risk. For investors seeking an AI stock that is significantly undervalued and poised to benefit from Trump-era tariffs and the ongoing trend of onshoring, we recommend exploring our comprehensive report on the most promising short-term AI stock opportunities. This strategic move by Artisan Value Fund underscores the importance of transparent communication and consistent performance in maintaining investor confidence.

More Articles
Madison Small Cap Fund Divests Confluent Stake After Acquisition Announcement
Madison Small Cap Fund has sold its holdings in Confluent, Inc. (CFLT) following the announcement of IBM's acquisition of the company for $11 billion. This decision was made as the fund does not anticipate competing bids, allowing them to reallocate capital to new opportunities. The fund's fourth-quarter 2025 performance was challenging, underperforming its benchmark, with healthcare being a significant negative contributor.
By Ramit SethiMar 16, 2026
Cryptocurrency Markets See Significant Gains, Bitcoin Tops $73,000
On Monday morning, Bitcoin surged past the $73,000 mark, propelled by substantial ETF inflows. Ethereum, XRP, and Dogecoin also experienced rallies, leading to a generally neutral market sentiment. Meme coin market capitalization saw a nearly 5% increase.
By Scott PapeMar 16, 2026
Madison Small Cap Divests from Cogent Communications Due to Strategic Concerns
Madison Small Cap Fund has exited its investment in Cogent Communications Holdings (CCOI), citing concerns over the company's dividend suspension and elevated leverage. The fund's initial thesis relied on a dividend cut and EBITDA growth, but a temporary suspension led to uncertainty regarding the stock's valuation. CCOI's shares have seen a significant decline, prompting Madison to reconsider its position.
By Natalie PaceMar 16, 2026
Encompass Health Corporation's Q4 Performance: A Deeper Look into Madison Small Cap Fund's Perspective
Madison Small Cap Fund's Q4 2025 investor letter revealed challenges, with the fund underperforming its benchmark, the Russell 2000 Index. Healthcare was the weakest sector, notably impacting Encompass Health Corporation (EHC), a leading inpatient rehabilitation services provider. Despite strong fundamentals, EHC's defensive nature clashed with a market seeking offense. The fund remains cautiously optimistic about the speculative market losing momentum. This article delves into these findings and broader market implications.
By Natalie PaceMar 16, 2026
Eli Lilly's Eczema Drug Shows Strong Skin Clearance In Phase 3 Pediatric Trial
Eli Lilly and Co. announced positive results from its Phase 3 ADorable-1 trial for Ebglyss (lebrikizumab-lbkz) in pediatric patients with moderate-to-severe atopic dermatitis, showing significant skin improvement and itch relief, with a safety profile consistent with previous studies. The company plans to submit these data to regulators for a potential label update.
By Natalie PaceMar 16, 2026